Research & Development Market Research Reports & Industry Analysis
Bringing R&D costs and times down, therefore, means there are many opportunities to improve efficiencies, advance technological innovation, and economize and optimize. The pharmaceutical R&D category tracks both drug pipeline reports, competitive R&D strategies, and markets important and ancillary to the research efforts themselves, including activities in the biotech and sector that impinge upon the process.
Research & Development Industry Research & Market Reports
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Virus Filtration Products
... at a CAGR of 12.4% over the analysis period 2024-2030. Virus Filtration Kits & Reagents, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.8 Billion by ... Read More
-
Cold Plasma
... CAGR of 14.8% over the analysis period 2024-2030. Atmospheric Regime, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$3.7 Billion by the end of the analysis ... Read More
-
Peptide Synthesis
... CAGR of 4.3% over the analysis period 2024-2030. Peptide Synthesis Reagent, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$161.7 Million by the end of the ... Read More
-
Protein Characterization and Identification
... 2030, growing at a CAGR of 13.2% over the analysis period 2024-2030. Protein Characterization & Identification Consumables, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$17.2 ... Read More
-
Bone Marrow Aspirate Concentrates
... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Bone Marrow Aspirate Concentrates Systems, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$178.5 ... Read More
-
In Vivo Contract Research Organization (CRO)
... reach US$8.0 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Smalll Molecules Modality, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and ... Read More
-
Genomics in Cancer Care
... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomics Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the ... Read More
-
Recombinant DNA Technology
... at a CAGR of 4.5% over the analysis period 2024-2030. Medical Recombinant DNA Technology, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$77.9 Billion by the ... Read More
-
Research Antibodies
... CAGR of 4.7% over the analysis period 2024-2030. Reagent, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$5.4 Billion by the end of the analysis period. ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Asthma Therapeutics
... CAGR of 2.3% over the analysis period 2024-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$10.7 Billion by the end of the analysis ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Bioburden Testing Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the ... Read More
-
Biobanks
... 7.7% over the analysis period 2024-2030. Physical / Real Biobanks, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$108.4 Billion by the end of the analysis ... Read More
-
Human Liver Models
... at a CAGR of 9.3% over the analysis period 2024-2030. Liver Organoids, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$250.6 Million by the end of ... Read More
-
Rat Model
... CAGR of 7.1% over the analysis period 2024-2030. Inbred Rat Model, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$901.6 Million by the end of the ... Read More
-
Protein Binding Assays
... at a CAGR of 9.4% over the analysis period 2024-2030. Equilibrium Dialysis Technology, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$342.2 Million by the end ... Read More
-
Protein Fractionation
... CAGR of 5.4% over the analysis period 2024-2030. Immunoglobulins, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$24.4 Billion by the end of the analysis period. ... Read More
-
Biotech Flavors
... CAGR of 6.7% over the analysis period 2024-2030. Vanilla & Vanillin Flavors, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$872.9 Million by the end of ... Read More
-
Bone Morphogenetic Proteins
... at a CAGR of 2.4% over the analysis period 2024-2030. Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2), one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$484.6 Million ... Read More
-
Quantum Computing in Healthcare
... 2030, growing at a CAGR of 36.9% over the analysis period 2024-2030. Quantum Computing Services, one of the segments analyzed in the report, is expected to record a 40.1% CAGR and reach US$452.4 Million by ... Read More
-
Bone Marrow Transplant
... at a CAGR of 4.1% over the analysis period 2024-2030. Autologous Transplant, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$8.7 Billion by the end of ... Read More
-
Biotech Business February 2025
... on biotechnology products and companies. It reports which universities offer licensing of biotechnology research, which companies have entered licensing agreements, as well as the financial health of biotechnology companies and their expected growth or decline. Read More
-
Hepatitis C Treatment
... at a CAGR of 10.7% over the analysis period 2024-2030. HCV Protease Inhibitors, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$25.3 Billion by the end ... Read More
-
Healthcare Contract Management Software
... 2030, growing at a CAGR of 19.3% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$7.1 Billion by the ... Read More
Research Assistance
